Supplementary Material

Treatment of Alzheimer's Disease in the New Era of Monoclonal Antibodies Against Cerebral Amyloid-β: Pharmacological Prescription and Knowledge in Argentina

Pharmacological Management of Alzheimer's Disease in Argentina

You have been invited to participate in an opinion study about pharmacological management of Alzheimer's Disease in Argentina. To carry out this evaluation, you must answer the following survey. In the future these data could be used for other research studies. All information collected will be kept under strict medical secrecy and anonymity. This study does not have industry funding and it is established that the researchers do not have any conflict of interest related to the project. Its performance will last less than 5 minutes. Do you want to participate?

- o Yes
- o No

Respondent Data:

- Age (number):
- Sex:
 - Male
 - o Female
 - o Another
- In which province or district do you practice healthcare?
 - o Buenos Aires
 - o City of Buenos Aires
 - Catamarca
 - Chaco
 - Chubut
 - o Córdoba

0	Corrientes	
0	Entre Ríos	
0	Formosa	
0	Jujuy	
0	La Pampa	
0	La Rioja	
0	Mendoza	
0	Misiones	
0	Neuquén	
0	Río Negro	
0	Salta	
0	San Juan	
0	San Luis	
0	Santa Cruz	
0	Santa Fe	
0	Santiago del Estero	
0	Tierra del Fuego	
0	Tucumán	
• Are you a doctor specializing in neurology, psychiatry, geriatric, or a resident of any of		
the mentioned specialties?		
0	Neurology	
0	Psychiatry	
0	Geriatric	
0	Resident	
0	Another	
• Years	of medical practice:	
• Do you consider yourself a specialist in cognitive disorders?		
0	Yes	
0	No	
0	Don't know	

Survey:

1) Which of the following groups of drugs do you prescribe in treatment of dementia due to Alzheimer's Disease? Vitamin/amino acid supplements Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) Nimodipine Citicoline Nimodipine- citicoline Memantine Idebenone Ergot derivatives Gingko Biloba Gangliosides Cerebrolysin Acetylcarnitine Resveratrol None Don't know Another 2) Which of the following groups of drugs do you prescribe in treatment of mild cognitive impairment due to Alzheimer's Disease? Vitamin/amino acid supplements Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) Nimodipine Citicoline Nimodipine- citicoline Memantine Idebenone

Ergot derivatives

0	Gingko Biloba
0	Gangliosides
0	Cerebrolysin
0	Acetylcarnitine
0	Resveratrol
0	None
0	Don't know
0	Another
3) Would	l it indicate monoclonal antibodies (MAB) against cerebral amyloid- β in treatment
of Alz	heimer's Disease?
0	Yes
0	No
_	Don't know
onswer to the question	the question 3 is "Yes" or "Don't know", continue to the question 4, otherwise on 7.
nswer to	
nswer to t	on 7.
nswer to the question 4) If you	on 7. going to start treatment with MAB in patients with suspected Alzheimer's disease,
nswer to the question 4) If you would	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial
nswer to the question 4) If you would assess	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment?
nswer to the question 4) If you would assess	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes
nswer to the question 4) If you would assess	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No
nswer to the question 4) If you would assess:	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know
nswer to the question 4) If you would assess:	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know Another
nswer to the question 4) If you would assess	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know Another ere available in Argentina, would you prescribe Aducanumab in the treatment of
nswer to the question 4) If you would assess	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know Another ere available in Argentina, would you prescribe Aducanumab in the treatment of imer's Disease?
nswer to the question 4) If you would assess:	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know Another ere available in Argentina, would you prescribe Aducanumab in the treatment of imer's Disease? Yes
nswer to the question 4) If you would assess:	going to start treatment with MAB in patients with suspected Alzheimer's disease, you request amyloid biomarkers (imaging or in cerebrospinal fluid) in the initial ment? Yes No Don't know Another ere available in Argentina, would you prescribe Aducanumab in the treatment of imer's Disease?

- 6) If you indicate MAB, in which stage or stages of Alzheimer's Disease would you indicate it?
 - o Mild cognitive impairment
 - Mild dementia
 - Moderate dementia
 - o Severe dementia
- 7) Which of the following statements would you say is a weakness of MAB treatment? You can choose more than one option
 - o Treated patients have slight cognitive improvement
 - o Lack of proven evidence on cerebral amyloid-β reduction
 - o Adverse effects outweigh benefits
 - High cost of treatment
 - o Treatment with MAB does not present significant weaknesses
 - o Don't know
 - Another
- 8) What are the most frequent adverse effects currently described associated with MAB?
 - o Cerebral edema (ARIA-E)
 - Headache
 - o Microhemorrhages/superficial siderosis (ARIA-H)
 - o Falls
 - Immunosuppression
 - o Oncogenesis
 - o Anaphylactic reaction
 - o None
 - O Don't know
 - Another
- 9) If an antipsychotic drug is required in treatment of disruptive psychotic symptoms in dementia due to Alzheimer's Disease, what of the following drugs would you use?
 - o Risperidone
 - o Quetiapine
 - Olanzapine

0	Pimavanserin	
0	Clozapine	
0	Promethazine	
0	Levomepromazine	
0	Aripiprazole	
0	Haloperidol	
0	Lurasidone	
0	None	
0	Don't know	
0	Another	
10) Which of the following drugs would you indicate in treatment of apathy in Alzheimer's		
disease?		
0	Sertraline	
0	Venlafaxine	
0	Bupropion	
0	Modafinil	
0	Armodafinil	
0	Escitalopram	
0	Methylphenidate	
0	None	
0	Don't know	
0	Another	
11) The effect of the dementia treatments currently recommended and available in Argentina		
is (You can choose more than one option):		
0	Temporarily stop neurodegeneration in some cases	
0	Improve cognitive symptoms in some cases	
0	Permanently stop neurodegeneration in some cases	
0	Improve cognitive symptoms in all cases	
0	Eliminate cerebral amyloid-β protein	
0	Reduce cerebral amyloid-β protein	
0	Eliminate cerebral tau protein	

- o Decrease cerebral tau protein
- o None
- o Don't know
- Another
- 1) How would you rate (from 0 to 10) the effectiveness of pharmacological treatments for dementia in Alzheimer's Disease in Argentina? Consider 0 as very poor effectiveness, and 10 as outstanding: